Kura Oncology, Inc.
corporate_fare Company Profile
Kura Oncology, Inc. (NASDAQ:KURA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for KURA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for KURA spans 4, 10-Q, 8-K.
Recent high-impact activity:
- Kura CEO Troy Wilson Buys 200,000 Shares for $1.5 Million Open-Market
- Kura's Q3 Revenue Misses by $10M Despite Narrower-Than-Expected Loss
- Kura Q3 10-Q: $13.9M KOMZIFTI Quarter, $492.1M Cash, New $275M Oberland Facility
- Kura Q3: KOMZIFTI Revenue Up 53% to $13.9M; Darlifarnib FDA Alignment
- KOMZIFTI Revenue Jumps 53% to $13.9M as Kura Lands FDA Alignment on Second Program
Financial Snapshot
Short Interest & Short Volume
7.86 days to coverFINRA reported short interest of 12,640,858 shares in KURA as of the October 30, 2026 settlement, a 11.7% decrease from the prior period — about 7.9 days to cover at its recent average daily volume. On November 20, 2026, 48.5% of KURA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for KURA, detected from its recent SEC filings · based on capital-structure filings through 2026-11-10.
New $150M ATM Program Registered · Replaces 2023 Shelf
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →